Last update July 25, 2022

Doxazosin Mesylate

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is an alpha-1-adrenergic blocking agent that is used for treatment of arterial hypertension and of obstructive symptoms resulting from benign prostatic hypertrophy. Oral administration once a day.

Its pharmacokinetic data, -moderately elevated molecular weight, high percentage of plasma protein binding and high volume of distribution (Pfizer 2017, Kirsten 1998, Elliot 1987)-, probably explain the negligible excretion observed in milk. (Pfizer 2017, Versmissen 2016, Jensen 2013 y 2014)

Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug may be used (Anderson 2018, Schaefer 2007 p685), especially during the neonatal period and/or in case of premature infants.

Alternatives

  • Methyldopa ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Doxazosin Mesylate in other languages or writings:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 65 - 68 %
Molecular weight 548 daltons
Protein Binding 98 - 99 %
VD 1.3 l/Kg
pKa 7.2 -
Tmax 2 (retard: 8 - 9) hours
19 - 22 hours
M/P ratio 0.1 -
Theoretical Dose 0.0004 - 0.0006 mg/Kg/d
Relative Dose 0.6 - 0.9 %

References

  1. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  2. PhI (Pharmascience Inc). Doxazosin. Drug Summary. 2017 Full text (in our servers)
  3. Pfizer. Doxazosina. Ficha técnica. 2017 Full text (in our servers)
  4. Versmissen J, Koch BC, Roofthooft DW, Ten Bosch-Dijksman W, van den Meiracker AH, Hanff LM, Visser W. Doxazosin treatment of phaeochromocytoma during pregnancy: placental transfer and disposition in breast milk. Br J Clin Pharmacol. 2016 Abstract
  5. (Jensen BP, Dalrymple JM, Begg EJ) Corrigendum: Transfer of doxazosin into breast milk. J Hum Lact. 2013 J Hum Lact. 2014 Abstract
  6. Jensen BP, Dalrymple JM, Begg EJ. Transfer of doxazosin into breast milk. J Hum Lact. 2013 Abstract
  7. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, second edition. London. 2007
  8. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Abstract
  9. Elliott HL, Meredith PA, Reid JL. Pharmacokinetic overview of doxazosin. Am J Cardiol. 1987 Abstract

Total visits

8,570

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM